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Previewscells, PSC-differentiated human progeni-
tors self-organized into 3D structures
and integrated into mouse renal struc-
tures in vitro.
Taguchi et al. described a thorough
stepwise protocol for PSC differentiation
that recapitulates the in vivo stepwise
development of the nascent mesoderm,
posterior nascent mesoderm, posterior
IM, and finally MM. The generated
metanephric nephron progenitors were
induced to mature further into renal tu-
bules using a well-established coculture
system with embryonic spinal cords.
Both proximal and distal tubules devel-
oped, as well as numerous glomerulus-
like structures including clusters of cells
expressing podocytemarkers. Transplan-
tation of the metanephric nephron pro-
genitors together with spinal cords under
the kidney capsule of immunodeficient
mice induced massive tubulogenesis.
Highly vascularized glomeruli were found
to integrate with the host vasculature,
which is a prerequisite for glomerular
function as a filtration unit. The authors
successfully extended this protocol to6 Cell Stem Cell 14, January 2, 2014 ª2014 Ehuman iPSCs, generating human meta-
nephric nephron progenitors that could
likewise mature into proximal and distal
tubules, as well as glomeruli, upon cocul-
ture with embryonic spinal cords in vitro.
Due to the variation in induction proto-
cols between these different studies, it is
possible that the 3D kidney structures
generated in vitro have differing degrees
of functional potential. Although the clear
vascularization of the de novo human
glomeruli described by Taguchi et al. sug-
gests a large step toward obtaining
functional kidney structures, this pos-
sibility needs to be directly tested, for
example by transplantation into a ne-
phrectomy-based kidney injury mouse
model, as recently demonstratedwith iso-
lated human nephron progenitors (Harari-
Steinberg et al., 2013). Use of kidney
injury mouse models is a prerequisite
to comprehend whether human trans-
planted PSC-derived kidney progenitor
cells, or their subsequent 3D kidney
derivatives, can integrate into the host
renal structures in vivo, including the
excretory nephrons and collecting ductslsevier Inc.to create a continuous passage for urine
for successful filtration repair in kidney
diseases.
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How TGF-b signaling switches from enforcing pluripotency to promoting mesendodermal differentiation
remains an open question. Recently in Cell Reports, Beyer et al. demonstrated that Hippo signaling compo-
nents recruit the NuRD complex to repress expression of key genes targeted by TGF-b and thus determine
whether TGF-b signaling will favor pluripotency or differentiation.TGF-b signaling influences numerous
cells types, directing cell-type-specific re-
sponses throughout developmental and
disease processes. In human embryonic
stem cells (hESCs), TGF-b signaling is
required to maintain pluripotency, and
yet it is also the key pathway that induces
differentiation of hESCs into mesendo-
derm (Oshimori and Fuchs, 2012). In arecent paper in Cell Reports, Beyer et al.
(2013) describe a new mechanism under-
lying these divergent responses to TGF-b
signaling.
The canonical TGF-b signaling pathway
is mediated through activation of the tran-
scription factors SMAD2 and SMAD3
(SMAD2/3). When these proteins are acti-
vated by phosphorylation, they form acomplex with SMAD4 and are retained in
the nucleus where they cooperate with
other transcription factors to form a stable
complex on DNA (Oshimori and Fuchs,
2012). Through context-dependent part-
nering with different transcription factors,
SMAD2/3 tend to occupy unique en-
hancers in different cell types (Mullen
et al., 2011).
Figure 1. Loss of TAZ/YAP and TEAD Results in Activation of Mesendodermal Genes Bound
by SMAD2/3
A set of key mesendodermal genes are bound by OCT4, SMAD2/3, SMAD4, FOXH1, TAZ/YAP, and TEAD
family members in hESCs. These genes are repressed in hESCs where TAZ/YAP and TEAD act to recruit
the NuRD complex (left). With mesendodermal differentiation, TAZ/YAP and TEAD no longer bind key
mesendodermal genes. In their absence the NuRD complex is released and mesendodermal genes are
activated in a process that is dependent on SMAD2/3 and FOXH1 (right).
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PreviewsIn ESCs, SMAD2/3 occupy the genome
with the ESC master transcription factors
OCT4 and NANOG (Brown et al., 2011;
Mullen et al., 2011). With removal of
serum and fibroblast growth factor from
hESC media, SMAD2/3 activation directs
mesendodermal differentiation (D’Amour
et al., 2005). It has remained unclear
how activation of SMAD2/3 transitions
from reinforcing to antagonizing hESC
pluripotency. Beyer et al. (2013) now
show that components of the Hippo
signaling pathway play a key role in deter-
mining how hESCs respond to activation
of SMAD2/3.
The authors first took a proteomics
approach to identify proteins from hESC
nuclear extracts that bound to a 400 bp
region of the NANOG promoter. The
NANOG gene is bound by OCT4,
NANOG, and SMAD2/3 in hESCs (Brown
et al., 2011; Mullen et al., 2011), and its
expression is induced during early mes-
endodermal differentiation (Greber et al.,
2008). Using mass spectrometry, the au-
thors identified components of the Hippo
signaling pathway that were associated
with the NANOG promoter. These factors
included TAZ, YAP, and TEAD family
members. The authors showed through
biochemical approaches that OCT4,
SMAD2/3, and TAZ/YAP/TEAD are part
of a physical complex on DNA. They
also found that depletion of TAZ and
YAP together or depletion of the four
TEAD family members was sufficient to
induce activation of key mesendodermal
genes. In addition, loss of these factors
also resulted in further induction of
OCT4 and NANOG expression, which is
associated with early mesendodermal dif-ferentiation (Greber et al., 2008). These
findings suggest that TAZ/YAP/TEAD act
to repress gene expression in hESCs.
To understand how components of the
Hippo signaling pathway repress mesen-
dodermal genes, the authors returned
to their proteomic analysis and identified
several components of the nucleosome
remodeling and deacetylase (NuRD)
complex that were also associated with
the NANOG promoter. The NuRD com-
plex has been implicated in regulating
ESC fate (Hu and Wade, 2012), and
depletion of multiple components of this
complex each produced a phenotype
similar to loss of TAZ and YAP or TEAD
family members. In addition, the pres-
ence of TAZ and YAP tend to be required
for normal levels of NuRD occupancy at
key genes. Taken together, these results
suggest that the repressive effects of
TAZ/YAP/TEAD are mediated through
recruitment of the NuRD complex.
SMAD2/3 and the mesendodermal
transcription factor FOXH1 bind to many
of the same genes in hESCs (Kim et al.,
2011). When the authors compared the
genome-wide binding sites for TEAD,
SMAD2/3 and OCT4 (TSO) with the bind-
ing sites for FOXH1, they found that 20%
of TSO sites were also occupied by
FOXH1. They confirmed co-occupancy
at key mesendodermal genes by chro-
matin immunoprecipitation (ChIP) and
then tested the effect of loss of FOXH1
and disruption of the TSO complex
on mesendodermal gene activation. As
expected, hESCs deficient in FOXH1 re-
tained normal expression of pluripotency
genes, suggesting that FOXH1 expres-
sion does not affect the pluripotent stateCell Stem Celof hESCs. In addition, hESCs deficient
in FOXH1 were not able to activate mes-
endodermal markers under differentiation
conditions, consistent with a block in
differentiation. Significantly, when TAZ,
YAP, and FOXH1 were depleted, hESCs
were no longer able to activate mesendo-
dermal genes in response to differentia-
tion signals. Thus, TAZ and YAP appear
to recruit the NuRD complex to genes
co-occupied by SMAD2/3, OCT4, and
FOXH1. Loss of TAZ and YAP, and pre-
sumably loss of TEAD, or loss of the
NURD complex all result in the induction
of these co-occupied genes in a pro-
cess that requires FOXH1. Therefore,
in hESCs, components of the Hippo
pathway appear to mediate repression
of TGF-b signaling by binding a set of
key mesendodermal genes. The loss of
binding of these Hippo factors that occurs
with differentiation acts as a switch to
allow rapid induction of mesendodermal
genes bound by OCT4, SMAD2/3, and
FOXH1 (Figure 1).
The Hippo signaling pathway is
conserved from yeast to mammals and
has been shown to affect ESC pluripo-
tency and to interact with TGF-b signaling
(Barry and Camargo, 2013). However,
this study provides the first evidence
that components of the Hippo pathway
are directly involved in repressing gene
expression in ESCs and that the presence
or absence of these Hippo factors con-
trols how developmental genes respond
to SMAD2/3 binding. These findings raise
the important question: what controls loss
of TAZ/YAP/TEAD binding during mesen-
dodermal differentiation? The authors
quantified expression of CTGF, a gene
that is occupied by TAZ/YAP/TEAD, but
not OCT4 or SMAD2/3. CTGF expression
was unchanged upon mesendodermal
differentiation, suggesting that Hippo
signaling may not have been altered.
However, TAZ/YAP have been shown to
be involved in regulating hESC pluripo-
tency, and YAP expression decreases
with differentiation of mESCs (Barry and
Camargo, 2013). Further understanding
of the expression, subcellular localization,
and genomic occupancy of TAZ/YAP and
TEAD family members during hESC differ-
entiation should shed further light on how
this pathway regulates transcriptional
responses to SMAD2/3 activation.
Integrating the concept of TAZ/YAP/
TEAD as transcriptional repressors intol 14, January 2, 2014 ª2014 Elsevier Inc. 7
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Previewsrecent discoveries should continue to
advance our understanding of how cells
respond to TGF-b signaling. For example,
cell cycle has recently been shown to
affect how hESCs respond to SMAD2/3
activation with hESCs in early G1 being
the most sensitive to mesendodermal dif-
ferentiation signals (Pauklin and Vallier,
2013). Hippo signaling regulates prolifera-
tion in many different cell types (Barry and
Camargo, 2013) where nuclear localiza-
tion of YAP or its homologs are associ-
ated with increased rates of cell division
and presumably a shorter duration of
G1. In hESCs loss of TAZ/YAP binding
is associated with induction of mesendo-
dermal genes by SMAD2/3, raising the
question of whether loss of TAZ/YAP
binding could be associated with longer8 Cell Stem Cell 14, January 2, 2014 ª2014 Eduration of G1 and contribute to activa-
tion of mesendodermal genes. Further
investigation of the interaction between
Hippo and TGF-b signaling will increase
our understanding of how they modulate
hESC state and provide insight into the
coordination of these two pathways in
development and disease.
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